Prasugrel News and Research RSS Feed - Prasugrel News and Research

Pre-treatment with prasugrel increases risk of bleeding without reducing risk of ischemic events

Pre-treatment with prasugrel increases risk of bleeding without reducing risk of ischemic events

In patients with non-ST-elevation acute coronary syndrome (NSTE- ACS), pre-treatment with the P2Y12 antagonist prasugrel prior to catheterization, significantly increases the risk of life-threatening bleeding without reducing the risk of major ischemic events, according to the results of the ACCOAST (A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction) trial. [More]
Older heart patients present unique challenges for determining optimal dosages of medications

Older heart patients present unique challenges for determining optimal dosages of medications

Older heart patients present unique challenges for determining the optimal dosages of medications, so a new study from researchers at Duke Medicine offers some rare clarity about the use of drugs that are used to treat patients with heart attacks. [More]
Study: New genetic marker predicts warfarin dose in African-Americans

Study: New genetic marker predicts warfarin dose in African-Americans

A newfound genetic marker promises to better predict warfarin dose in African-Americans, according to a study published online today in The Lancet. If confirmed in further studies, the finding may help to avert more of the bleeds and blood clots that come when a patient's starting dose misses the drug's narrow safety window. [More]
TRILOGY-ACS platelet function substudy results revealed

TRILOGY-ACS platelet function substudy results revealed

The platelet function substudy of the TRILOGY-ACS trial shows that there is no significant difference between prasugrel and clopidogrel in cardiovascular mortality, myocardial infarction, or stroke outcomes. [More]
Most patients taking common blood-thinning drugs may be receiving wrong dosage levels

Most patients taking common blood-thinning drugs may be receiving wrong dosage levels

Cardiology researchers at the Intermountain Medical Center Heart Institute have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to a new study. [More]
Cause of heart attacks or strokes may be different in some patients treated with anti-platelet drugs

Cause of heart attacks or strokes may be different in some patients treated with anti-platelet drugs

The cause of heart attacks or strokes among some patients treated with anti-platelet drugs may be different than for patients who have undergone surgical procedures to restore blood flow, according to researchers at Duke Medicine. [More]
Prasugrel reduces cardiovascular events among patients managed medically for ACS

Prasugrel reduces cardiovascular events among patients managed medically for ACS

A study has found that the anti-clotting medication prasugrel reduced cardiovascular events among patients who present with an acute coronary syndrome and are managed medically after an angiogram is performed to determine coronary anatomy. [More]
MADONNA: Personalized antiplatelet therapy savior for angioplasty patients?

MADONNA: Personalized antiplatelet therapy savior for angioplasty patients?

Personalized antiplatelet treatment may improve cardiac outcomes after percutaneous coronary intervention, researchers suggest. [More]
AstraZeneca’s ticagrelor receives Class I recommendation from ESC

AstraZeneca’s ticagrelor receives Class I recommendation from ESC

AstraZeneca today announced that ticagrelor, an oral antiplatelet medicine, received a Class I recommendation from the European Society of Cardiology (ESC) in the revised "Guidelines on the Management of Acute Myocardial Infarction in Patients Presenting with Persistent ST-Segment Elevation (STEMI)" guidelines. [More]
Personalized antiplatelet treatment leads to better outcomes in patients undergoing PCI

Personalized antiplatelet treatment leads to better outcomes in patients undergoing PCI

Personalized antiplatelet treatment leads to better outcomes than standard antiplatelet treatment in patients undergoing coronary stent implantation, according to results from the MADONNA study presented at ESC Congress 2012. [More]
Prasugrel as safe as clopidogrel in preventing heart attack, stroke and death

Prasugrel as safe as clopidogrel in preventing heart attack, stroke and death

The first trial to study patients with acute coronary syndrome who do not undergo coronary stenting or bypass surgery found no significant difference between two anti-clotting drugs - prasugrel and clopidogrel - in preventing the first occurrence of death, heart attack or stroke, according to Duke University Medical Center cardiologists. [More]
HCRI announces successful completion of randomization in DAPT Study

HCRI announces successful completion of randomization in DAPT Study

The Harvard Clinical Research Institute (HCRI) announced today the successful completion of randomization in the DAPT Study, with the total number of patients randomized exceeding the upper goal set for the Study. [More]
Ticagrelor ‘now on equal footing’ with other antiplatelets

Ticagrelor ‘now on equal footing’ with other antiplatelets

The platelet aggregation inhibitor ticagrelor is now considered of equal effectiveness to clopidogrel and prasugrel for patients who have experienced a heart attack or have unstable angina, a report states. [More]
Ticagrelor ‘now on equal footing’ with other antiplatelets

Ticagrelor ‘now on equal footing’ with other antiplatelets

The platelet aggregation inhibitor ticagrelor is now considered of equal effectiveness to clopidogrel and prasugrel for patients who have experienced a heart attack or have unstable angina, a report states. [More]
JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE. [More]
Janssen receives FDA complete response letter for XARELTO sNDA

Janssen receives FDA complete response letter for XARELTO sNDA

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS). [More]
Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen Research & Development, LLC announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO, an oral anticoagulant, to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome. [More]

Aggredyne closes $3 million Series A convertible preferred stock financing

Aggredyne, Inc., a Houston-based biomedical diagnostics company that is defining a new standard for platelet function testing, sold out and closed a $3 million Series A convertible preferred stock financing. [More]
The Lancet acknowledges world's first bedside genetic test

The Lancet acknowledges world's first bedside genetic test

Developed in Canada and conducted by researchers from the University of Ottawa Heart Institute, in partnership with Spartan Bioscience, the world's first bedside genetic test has received acknowledgment by The Lancet, the world's leading general medical journal. [More]
CRF initiates Harmonizing Outcomes with Revascularization and Stents in AMI II trial

CRF initiates Harmonizing Outcomes with Revascularization and Stents in AMI II trial

The Cardiovascular Research Foundation (CRF) today announced the initiation of the HORIZONS-AMI II randomized trial, evaluating Promus Element platinum-chromium everolimus-eluting stents versus Omega bare-metal stents in patients with heart attack undergoing primary angioplasty with bivalirudin anticoagulation. [More]